Fairmont Chateau Whistler Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

NOTES:
This meeting will be conducted in English.

All programs are subject to change. Check this site for updates.


This meeting is part of the Global Health Series

Download Flyer

Twitter hashtag for this meeting: #KScancerimm

Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology (C7)

Scientific Organizers: Robert D. Schreiber, James P. Allison, Philip D. Greenberg and Glenn Dranoff


March 19—23, 2017

Fairmont Chateau Whistler, Whistler, British Columbia, Canada


Sponsored by Astellas Pharma Inc., AstraZeneca, BioLegend, Inc., Bristol-Myers Squibb Company, Cell Research, Cell Signaling Technology, Inc., Genentech, Inc., Genmab A/S, ImmunoGen, Inc., Incyte Corporation, Juno Therapeutics, Merck & Co., Inc., Mersana Therapeutics, MorphoSys AG, OncoMed Pharmaceuticals, Inc. ,Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche, Sangamo Therapeutics, Inc., Takeda Pharmaceutical Company Limited and TESARO, Inc. Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.


Meeting is SOLD OUT. We are no longer accepting names on the waitlist. You may send any questions or comments to info@keystonesymposia.org
BEWARE of booking lodging through companies unaffiliated with Keystone Symposia. Click here for more details.

Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies.

** Registration currently unavailable **



Discounted Abstract Deadline: November 16, 2016


Abstract Submission Fee: 100.00 USD*
Submission by this date receives 50.00 USD discount.
*50.00 USD will be applied to Registration Fee when you register

Abstract Details: It is best to submit your abstract early. Abstract and registration spaces are limited and may fill prior to the abstract or discounted registration deadlines. Submitting an abstract does not constitute or guarantee registration.

Submitting your abstract early allows us to:
  • submit your abstract to organizers to be considered for a short talk
  • accept your abstract online
  • include your abstract on our website and in our secure mobile app
  • reserve your space at the meeting for a poster presentation.**
**Submitting an abstract does not constitute or guarantee registration.
(The Abstract Deadline: is December 19, 2016)

Global Health Travel Award Deadline: October 18, 2016


Global Health Travel Award Details: You MUST complete your Global Health Travel Award appplication by the Global Health Travel Award Deadline and complete the other required steps (verify your contact information and submit a recommendation letter) to be considered for a travel award.


Click here to learn more about Global Health Travel Awards.

Scholarship Deadline: November 16, 2016


Scholarship Details: You MUST submit your abstract by the Scholarship Deadline and complete the other required steps (submit a scholarship application and submit a mentor letter) to be considered for a scholarship.

Click here to learn more about Scholarships.

Abstract Deadline: December 19, 2016


Abstract Submission Fee: 100.00 USD*
*50.00 USD will be applied to Registration Fee when you register

Details: It is best to submit your abstract early. Abstract and registration spaces are limited and may fill prior to the abstract or discounted registration deadline. Submitting an abstract does not constitute or guarantee registration.

Submitting your abstract by the Abstract Deadline allows us to:
  • submit your abstract to organizers to be considered for a short talk
  • include your abstract on our website and in our secure mobile app
  • reserve your space at the meeting for a poster presentation.**
**Submitting an abstract does not constitute or guarantee registration.
Abstracts submitted after the Abstract Deadline will NOT be considered for a short talk.

(Discounted Abstract Deadline: is November 16, 2016)

Discounted Registration Deadline: January 18, 2017


Registration Fee: 845.00 USD* (includes 150.00 USD discount)
Student Registration Fee: 620.00 USD* (must complete student verification form)

*Includes 50.00 USD of your abstract submission fee

After the Discounted Registration Deadline:


Registration Fee: 995.00 USD*
Student Registration Fee: 770.00 USD* (must complete student verification form)

*Includes 50.00 USD of your abstract submission fee

Registration spaces are limited and may fill prior to discounted registration deadline.

Please be advised that a few meeting participants have received calls and emails from a number of different housing services - "Exhibitors Housing Services", "Global Housing", etc. THESE COMPANIES ARE NOT AFFILIATED WITH KEYSTONE SYMPOSIA and are not authorized by Keystone Symposia to contact you. These companies may tell you that the meeting is filling and seek to take your lodging reservation and obtain your credit card number. We highly recommend that you not make a reservation with these companies or any other housing service! These companies' representations to participants have been misleading. Please report to Keystone Symposia any calls or correspondence you might have received and book only through the lodging link on our website, an established travel agency, or directly with the hotel.
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


The meeting will begin on Sunday, March 19 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, March 23 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, March 24 in order to fully experience the meeting.

SUNDAY, MARCH 19

16:00—20:00
Arrival and Registration

Macdonald Foyer
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Macdonald Foyer

MONDAY, MARCH 20

07:00—08:00
Breakfast

Frontenac/Empress Ballrooms
08:00—09:30
Welcome and Keynote Session
Registered attendees can view abstracts starting on 02/19/2017

Macdonald Ballroom
* Robert D. Schreiber, Washington University School of Medicine, USA

Glenn Dranoff, Novartis Institutes for BioMedical Research, USA
Mechanisms of Protective Tumor Immunity

Andreas G. Plückthun, University of Zürich, Switzerland
Future Biologics: Exploiting the Opportunities for Protein Engineering

Coffee Break

09:50—11:45
Multimodal Approaches to Immunotherapy
Registered attendees can view abstracts starting on 02/19/2017

Macdonald Ballroom
* Robert D. Schreiber, Washington University School of Medicine, USA
Personalized Cancer Vaccines

Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA
From the Clinic to the Lab: Investigating Immune Responses to Immune Checkpoint Therapies

Nicholas P. Restifo, NCI, National Institutes of Health, USA
Genome-Scale CRISPR-Cas9 Screen Identifies Genes Essential for T Cell-Based Cancer Therapies

11:45—17:00
On Own for Lunch

11:45—13:00
Poster Setup

Frontenac/Empress Ballrooms
13:00—22:00
Poster Viewing

Frontenac/Empress Ballrooms
14:30—16:30
Workshop 1: Neoantigens, Vaccines and Responses

Macdonald Ballroom
Nicholas K. Akers, Icahn School of Medicine at Mount Sinai, USA
Modeling Tumor Immuno-Dynamics to Predict Patient Survival & Immunotherapy Efficacy

Govinda Sharma, BC Cancer Agency, Canada
A Novel High-Throughput Screening Approach for the Detection of Cytotoxic T-Cell Receptor Epitopes

Sanja Stevanovic, NCI, National Institutes of Health, USA
Landscape of Immunogenic Tumor Antigens in Successful Immunotherapy of Virally-Induced Epithelial Cancer

Alice Tzeng, Cleveland Clinic Lerner College of Medicine, USA
Temporally Programmed CD8alpha+ DC Activation Enhances Combination Cancer Immunotherapy

Aileen Li, Harvard University, USA
Mesoporous Silica (MPS) Vaccine to Enhance Anti-Tumor Immunity

* Jay A. Berzofsky, NCI, National Institutes of Health, USA
Translation of Cancer Vaccines from Mice to Human Clinical Trials

16:30—17:00
Coffee Available

Macdonald Foyer
17:00—19:15
Immunosuppressive Cells in the Tumor Microenvironment
Registered attendees can view abstracts starting on 02/19/2017

Macdonald Ballroom
* Glenn Dranoff, Novartis Institutes for BioMedical Research, USA

Alexander Y. Rudensky, HHMI/Memorial Sloan Kettering Cancer Center, USA
Tregs in Cancer Immunity

Vincenzo Bronte, University of Verona, Italy
Role of Myeloid-Derived Suppressor Cells in Tumor Immunity

Alberto Mantovani, Humanitas University, Italy
Role of Macrophages in Tumor Immunity

Garry P. Nolan, Stanford University, USA
System-Wide Order, from Disorder, at the Cancer-Immune Interface

19:15—20:15
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Frontenac/Empress Ballrooms
19:30—22:00
Poster Session 1

Frontenac/Empress Ballrooms

TUESDAY, MARCH 21

07:00—08:00
Breakfast

Frontenac/Empress Ballrooms
08:00—11:15
Cancer Immunotherapy: Targeting Immune Checkpoints
Registered attendees can view abstracts starting on 02/19/2017

Macdonald Ballroom
* Ira Mellman, Genentech, Inc., USA
PD-1/PD-L1

Riccardo Mezzadra, NKI-AvL, Netherlands
Short Talk: Identification of CMTM6 and CMTM4 as PD-L1 Protein Regulators

Andrew D. Weinberg, Earle A. Chiles Research Institute/Oregon Health & Science University, USA
OX40 Agonists: Past, Present and Future

Coffee Break

Ana Carrizosa Anderson, Harvard Medical School, USA
Targeting Tim-3 in Cancer

Randolph J. Noelle, Dartmouth College, USA
Targeting the VISTA Pathway in Oncology

Vinidhra Mani, Harvard Medical School, USA
Short Talk: Visualizing the Mechanistic Basis of Checkpoint Blockade Therapy in Cancer

11:15—17:00
On Own for Lunch

11:15—13:00
Poster Setup

Frontenac/Empress Ballrooms
13:00—22:00
Poster Viewing

Frontenac/Empress Ballrooms
14:30—16:30
Workshop 2: Cellular Engineering and Therapy

Macdonald Ballroom
* Stanley R. Riddell, Fred Hutchinson Cancer Research Center, University of Washington, USA

Mauro Castellarin, University of Pennsylvania, USA
A Comparison of Affinity-Tuned Her2 CARs Using a New Mouse Model for On-Target Off-Tumor CAR T Cell Cytotoxicity

Ashwini Balakrishnan, Fred Hutchinson Cancer Research Institute, USA
Designed Ankyrin Repeat Proteins (DARPins) as Recognition Motifs in Chimeric Antigen Receptors

Kristin Anderson, University of Washington, USA
Engineering Adoptive T Cell Therapy for Efficacy in Ovarian Cancer

Stefanie Bailey, Medical University of South Carolina, USA
CD26high T Cells have a Natural Capacity to Migrate and Persist in Multiple Tumor Models

Natalie Ann Vandeven, University of Washington, USA
Novel Platform for Identifying Rare Antigen-Specific CD4 T Cells in Merkel Cell Carcinoma patients

Debattama Sen, Harvard Medical School, USA
The Epigenetic Landscape of T Cell Exhaustion

16:30—17:00
Coffee Available

Macdonald Foyer
17:00—19:00
Cancer Immunotherapy: Combinatorial Approaches
Registered attendees can view abstracts starting on 02/19/2017

Macdonald Ballroom
* James P. Allison, University of Texas MD Anderson Cancer Center, USA
Inhibition of Immune Checkpoints

Sandra Demaria, Weill Cornell Medical College, USA
Radiotherapy Needs to Go Viral to Increase Responses to Checkpoint Inhibitors

Antoni Ribas, University of California, Los Angeles, USA
Overcoming Resistance to PD-1 Blockade Therapy

Alyssa K. Kosmides, Johns Hopkins University, USA
Short Talk: Immunoswitch Particles: A New Approach to Cancer Immunotherapy

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Frontenac/Empress Ballrooms
19:30—22:00
Poster Session 2

Frontenac/Empress Ballrooms

WEDNESDAY, MARCH 22

07:00—08:00
Breakfast

Frontenac/Empress Ballrooms
08:00—11:15
Cancer Immunotherapy: Cancer Vaccines that Work and Why
Registered attendees can view abstracts starting on 02/19/2017

Macdonald Ballroom
* Elizabeth M. Jaffee, Johns Hopkins University, USA
Vaccine-Based Combinatorial Immunotherapy Can Convert Pancreatic Cancers into Immunologic Diseases

Cornelia L. Trimble, Johns Hopkins University School of Medicine, USA
High-Dimensional Analyses of the Mucosal Microenvironment in Precancerous, Intraepithelial Cervical HPV Disease

Coffee Break

Catherine Ju-Ying Wu, Dana-Farber Cancer Institute, USA
Developing and Improving Personalized Neoantigen-Targeting Cancer Vaccines

Ugur Sahin, TRON – Translationale Oncology, Germany
Individualizing Cancer Treatment by mRNA Therapies

Danielle M. Lussier, Washington University in St. Louis, USA
Short Talk: Subclinical Irradiation-Induced Neoantigens Enhance Immunotherapy of Cancers with Low Mutational Loads

Amanda Lulu, University of Virginia, USA
Short Talk: Pre-Existing Immune Memory in Healthy Donors to Cancer-Associated Phosphopeptides

11:15—17:00
On Own for Lunch

11:15—13:00
Poster Setup

Frontenac/Empress Ballrooms
13:00—22:00
Poster Viewing

Frontenac/Empress Ballrooms
16:30—17:00
Coffee Available

Macdonald Foyer
17:00—19:00
Inflammation and the Tumor Microenvironment
Registered attendees can view abstracts starting on 02/19/2017

Macdonald Ballroom
* Michael Karin, University of California, San Diego, USA
Immune Regulation of Liver Cancer: Chronic Hepatitis Promotes HCC Development by Dismantling Cancer Immunosurveillance

Shannon J. Turley, Genentech, Inc., USA
Leukocyte Function and Positioning in Diverse Stromal Niches

Thomas Gajewski, University of Chicago, USA
Tumor-Intrinsic Mediators of T Cell-Inflamed Versus Non-Inflamed Tumor Microenvironment

Evan W. Newell, Singapore Immunology Network, SigN, Singapore
Short Talk: Deep Profiling of Human Hepatocellular Carcinoma Immune Infiltrates: Involvement of CD103+ Resident Memory-Like T and NK Cells

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Frontenac/Empress Ballrooms
19:30—22:00
Poster Session 3

Frontenac/Empress Ballrooms

THURSDAY, MARCH 23

07:00—08:00
Breakfast

Frontenac/Empress Ballrooms
07:30—08:00
Poster Setup

Frontenac/Empress Ballrooms
08:00—17:00
Poster Viewing

Frontenac/Empress Ballrooms
08:00—11:15
Cancer Immunotherapy: Cellular Engineering
Registered attendees can view abstracts starting on 02/19/2017

Macdonald Ballroom
* Philip D. Greenberg, University of Washington, USA
Adoptive T Cell Therapy with TCR-Engineered T Cells

Michel Sadelain, Memorial Sloan Kettering Cancer Center, USA
Targeting CARs to the TRAC Locus Enhances T Cell Potency

Coffee Break

Carl H. June, University of Pennsylvania, USA
CAR-T Therapy of ALL

Stanley R. Riddell, Fred Hutchinson Cancer Research Center, University of Washington, USA
CAR-T Cells for Hematopoietic and Solid Tumors

Agne Taraseviciute, Seattle Children's Research Institute, USA
Short Talk: A Non-Human Primate Model That Recapitulates B Cell-directed Chimeric Antigen Receptor (CAR) T cell-mediated Cytokine Release Syndrome (CRS) and Neurologic Toxicity

Daniel T. Harris, University of Illinois, USA
Short Talk: A Comparison of T Cell Sensitivity using TCR and CAR Constructs with the Same pepMHC Binding Domain

11:15—12:15
Lunch

Frontenac/Empress Ballrooms
12:00—14:30
Poster Session 4

Frontenac/Empress Ballrooms
14:30—16:30
Workshop 3: A Deeper Dive into Cancer Immunotherapy

Macdonald Ballroom
* Evan W. Newell, Singapore Immunology Network, SigN, Singapore

Brian Christopher Miller, Dana-Farber Cancer Institute, USA
Dissecting Mechanisms of anti-PD-1 Therapy with Massively Parallel Single-Cell RNA-Sequencing

Wouter Scheper, Netherlands Cancer Institute, Netherlands
Unbiased Single-Cell TCR Analysis Reveals Infrequent Tumor-Reactivity Among T Cells Infiltrating Human Cancers

Spencer C. Wei, University of Texas MD Anderson Cancer Center, USA
Distinct Cellular Mechanisms Mediate Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade

Yonit Lavin, Mount Sinai School of Medicine, USA
High Dimensional Analysis of Untreated Early Lung Cancer Lesions Reveals Novel Myeloid Immune Responses to Tumor

Ken-Edwin Aryee, University of Massachusetts Medical School, USA
Humanized Mouse; A Model for Understanding Tumor-Immune System Interactions

Aya Ludin Tal, Harvard University, USA
The Zebrafish as a Model for T Cell Recruitment to Melanoma

16:30—17:00
Coffee Available

Macdonald Foyer
17:00—18:45
Nex-Gen Technologies
Registered attendees can view abstracts starting on 02/19/2017

Macdonald Ballroom
Darrell J. Irvine, Massachusetts Institute of Technology, USA
Combining Lymph Node Targeting Cancer Vaccines with Systemic Immunotherapy to Recruit an Innate and Adaptive Attack Against Established Tumors

* Lisa M. Coussens, Oregon Health & Science University, USA
Monitoring Inflammation in Cancer by Multi-Plex in situ Imaging

Jim R. Heath, California Institute of Technology, USA
Micro- and Nanotechnologies for Personalizing Cancer Immunotherapy

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Registered attendees can view abstracts starting on 02/19/2017

Macdonald Ballroom
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Frontenac/Empress Ballrooms
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Frontenac

FRIDAY, MARCH 24

 
Departure


*Session Chair †Invited, not yet responded.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

Astellas Pharma Inc. AstraZeneca
Bill & Melinda Gates Foundation BioLegend, Inc.
Bristol-Myers Squibb Company Cell Research
Cell Signaling Technology, Inc. Genentech, Inc.
Genmab A/S ImmunoGen, Inc.
Incyte Corporation Juno Therapeutics
Merck & Co., Inc. Mersana Therapeutics
MorphoSys AG OncoMed Pharmaceuticals, Inc.
Pfizer Inc. Regeneron Pharmaceuticals, Inc.
Roche Sangamo Therapeutics, Inc.
Takeda Pharmaceutical Company Limited TESARO, Inc.

We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge additional support for this conference from:

Adipogen International
American Association for Cancer Research (AACR)


Cellcion, LLC

InSphero Inc.
Opsona Therapeutics Ltd
Personalis Inc.


We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Novartis Institutes for BioMedical Research


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Assistant Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676